Associations between the genetic polymorphisms of MTHFR and outcomes of methotrexate treatment in rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 28, Issue 5, 2010, Pages 728-733

  Xiao, H ^a   Xu, J ^a   Zhou, X ^a   Stankovich, J ^b   Pan, F ^a   Zhang, Z ^a   Xu, S ^a   Lian, L ^a   Ding, C ^b,c  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TASMANIA   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

5, 10 methylenetetrahydrofolate reductase; Adverse events; Clinical response; Genetic polymorphisms; Rheumatoid arthritis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATININE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHINESE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE DURATION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INDIGESTION; JOINT SWELLING; LEUKOCYTE COUNT; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORNING STIFFNESS; NAUSEA; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE FREQUENCY; HUMANS; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650579712     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. MYLLYKANGAS-LUOSUJARVI R, AHO K, KAUTIAINTEN H et al.: Shortening of life span and causes of excess mortality in a population based series of subjects with rheumatoid arthritis. Clin Exp Rheumatol 1995;13:149-53.
2. WEISMAN MH, FURST DE, PARK GS et al.: Risk genotype in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum 2006;54:607-12.
3. WESSELS JA, DE VRIES-BOUWSTRO JK, HEIJ-MANS BT et al.: Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate parthway enzymes. Arthritis Rheum 2006;54:1087-95.
4. VEN EDE AE, LAAN RF, BLOM HJ et al.: Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (OXF.), 2002;41:658-65.
5. ROZEN R.: Molecular genetics of methylenetetrahydrofolate reductase deficiency. J Inherit Metab Dis 1996;19:589-94.
6. KREMER JM: Toward a better understanding of methotrexate (review). Arthritis Rheum 2004;50:1370-82.
7. CRONSTEIN BN: The mechanism of action of methotrexate (review). Rheum Dis Clin North Am 1997;23:739-55.
8. URANO W, TANIGUCHI A, YAMANAKA H et al.: Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus methylenetetrahydrofolate reductase gene and haplotype analyses. Pharmacogenetics 2002;12:183-90.
9. KUMAGAIK K, HIYAMA K, OYAMA T et al.: Polymorphisms in the thymidylate synthase and MTHFR genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 2003;11:593-600.
10. HUGHES LB, BEASLEY TM, PATEL H et al.: Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann Rheum Dis 2006;65:1213-18.
11. MARTÍNEZ LOPEZ JA, LOZA E, CARMONA L: Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding). Clin Exp Rheumatol 2009;27:678-84.
12. FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
13. MILLER SA, DYKES DD, POLESKY HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
14. SHI YY, HE L: SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005;15:97-8.
15. WINEGRAD S, WEISBERG I: A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Circ Res 1998;83:60-72.
16. FROSST P, BLOM HJ, MILOS R et al.: A candidate genetic risk factor for vascular disease: a commonmutationinmethylenetetrahydrofolatereductase. Nat Genet 10:111-3.
17. VANDERPUT NM, GABREELS F, STEVENS EM et al.: A second common mutation in the methylenetetrahydrofolate reductase gene: anadditional risk factor for neural-tube defects? Am J Hum Genet 62:1044-51.
18. RADY PL et al.: Genetic polymorphisms of methylenetetrahydrofolate reductase (MTH-FR) and methionine synthase reductase (MTRR) in ethnic populations in Texas; a report of a novel MTHFR polymorphic site, G1793A. Am J Med Genet 2002;107:162-8.
19. BOTTIGER AK, HURTIG WA, SJOSTROM M et al.: Association of total plasma homocysteine with methylenetetrahydrofolate reductase genotypes 677C >T, 1298A >C, and 1793G >A and the corresponding haplotypes in Swedish children and adolescents. Int J Mol Med 2007;19:659-65
20. TARABORELLI M, ANDREOLI L, ARCHETTI S et al.: Methylenetetrahydrofolate reductase polymorphisms and methotrexate: no association with response to therapy nor with drug-related adverse events in an Italian population of rheumatic patients. Clin Exp Rheumatol 2009;27:499-502.
21. MOHAMMAD A, KILCOYNE A, BOND U et al.: Methotrexate information booklet study 2008. Clin Exp Rheumatol 2009;27:649-50.
22. FISHER MC, CRONSTEIN BN: Meta-analysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J Rheumatol 2009;36:539-45.
23. KURZAWSKI M, PAWLIK A, SAFRANOW K et al.: 677C >T and 1298A >C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics 2007;8:1551-9) (Pubitemid 350286399)
24. DERVIEUX T, WESSELS JA, VAN der STRAATEN T et al.: Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. Pharmacogenet Genomics 2009; Oct. 24 (Epub ahead of print).